Doses - THIOGUANINE
For acute lymphocytic and granulocytic leukemia:Dogs:
a) 40 mg/m2 PO once daily (q24 hours) for 4-5 days, then every 3rd day thereafter.(Jacobs, Lumsden et al. 1992)Cats:
a) 25 mg/m2 PO once daily (q24 hours) for 1-5 days, then every 30 days thereafter asnecessary. (Jacobs, Lumsden et al. 1992)
Monitoring Parameters - 1) Hemograms (including platelets) should be monitored closely; initially every 1-2 weeks and every 1-2 months once on maintenance therapy. It is recommended bysome clinicians that if the WBC count drops to between 5, 000-7, 000 cells/mm3 the dose be reducedby 25%. If WBC count drops below 5, 000 cells/mm3 treatment should be discontinued untilleukopenia resolves; 2) Liver function tests; serum amylase, if indicated; 3) Efficacy
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related neoplasms or mortality. Clients should contact veterinarianshould the animal exhibit symptoms of abnormal bleeding, bruising, anorexia, vomiting, jaundice orinfection.
Although, no special precautions are necessary with handling intact tablets, it is recommended towash hands after administering the drug.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None
Dogs: 
a) 40 mg/m2 PO once daily (q24 hours) for 4-5 days, then every 3rd day thereafter.(Jacobs, Lumsden et al. 1992)Cats: 
a) 25 mg/m2 PO once daily (q24 hours) for 1-5 days, then every 30 days thereafter asnecessary. (Jacobs, Lumsden et al. 1992) Monitoring Parameters - 1) Hemograms (including platelets) should be monitored closely; initially every 1-2 weeks and every 1-2 months once on maintenance therapy. It is recommended bysome clinicians that if the WBC count drops to between 5, 000-7, 000 cells/mm3 the dose be reducedby 25%. If WBC count drops below 5, 000 cells/mm3 treatment should be discontinued untilleukopenia resolves; 2) Liver function tests; serum amylase, if indicated; 3) Efficacy
Client Information - Clients must be briefed on the possibilities of severe toxicity developingfrom this drug, including drug-related neoplasms or mortality. Clients should contact veterinarianshould the animal exhibit symptoms of abnormal bleeding, bruising, anorexia, vomiting, jaundice orinfection.
Although, no special precautions are necessary with handling intact tablets, it is recommended towash hands after administering the drug.
Dosage Forms/Preparations/FDA Approval Status/Withholding Times - Veterinary-Approved Products: None